2001 serological survey in the Czech Republic--poliomyelitis
Language English Country Czech Republic Media print
Document type Journal Article
PubMed
15080257
Knihovny.cz E-resources
- MeSH
- Child MeSH
- Adult MeSH
- Infant MeSH
- Middle Aged MeSH
- Humans MeSH
- Adolescent MeSH
- Poliomyelitis blood epidemiology immunology prevention & control MeSH
- Poliovirus Vaccine, Oral administration & dosage MeSH
- Poliovirus immunology MeSH
- Child, Preschool MeSH
- Antibodies, Viral blood MeSH
- Data Collection MeSH
- Serologic Tests MeSH
- Check Tag
- Child MeSH
- Adult MeSH
- Infant MeSH
- Middle Aged MeSH
- Humans MeSH
- Adolescent MeSH
- Child, Preschool MeSH
- Publication type
- Journal Article MeSH
- Geographicals
- Czech Republic epidemiology MeSH
- Names of Substances
- Poliovirus Vaccine, Oral MeSH
- Antibodies, Viral MeSH
Regular vaccination against poliomyelitis was started in 1960 with oral polio vaccine (OPV). Since 1992 a trivalent OPV has been administered in five doses within a nationwide vaccination campaign. The immunization coverage varies between 96.8% and 98.2% after 4 OPV doses, reaching 98.0% to 98.9% after the fifth dose. No case of indigenous poliomyelitis has been reported in the Czech Republic since the second half of 1960. In 2001, 3,230 sera were tested for the presence of antibodies against poliovirus of types 1, 2 and 3 using a virus neutralization microassay. The prevalence rates of antibodies vary between 96.0% and 100% for types 1 and 2 and between 95.1% and 100% for type 3, with the exception of the highest age group, in which the prevalence rates of antibodies against poliovirus of all three types are 92.2%.
